Recent developments in Miller Fisher syndrome and related disorders
- 1 October 2005
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Neurology
- Vol. 18 (5), 562-566
- https://doi.org/10.1097/01.wco.0000173284.25581.2f
Abstract
Miller Fisher syndrome is a localized variant of Guillain-Barré syndrome, characterized by ophthalmoplegia, areflexia and ataxia. Bickerstaff's brainstem encephalitis is a related syndrome in which upper motor neurone features accompany the classic triad. Anti-GQ1b antibodies are uniquely found in both conditions and are believed to be pathogenic. Infectious illnesses usually precede Miller Fisher syndrome. The clearest associations have been described with Haemophilus influenzae and Campylobacter jejuni infection. Raised cerebrospinal fluid protein is seen in 60% of patients, but clinical features and anti-GQ1b antibody testing are diagnostically more informative. Experimental studies demonstrating complement-dependent neuromuscular block may be relevant to the clinical pathophysiology of Miller Fisher syndrome. Recent neurophysiological studies suggest abnormal neuromuscular transmission occurs in some cases of Miller Fisher syndrome and Guillain-Barré syndrome. Recent mouse models have demonstrated that presynaptic neuronal membranes and perisynaptic Schwann cells are targets for anti-GQ1b antibody attack. The elimination of antiganglioside antibodies from the circulation through specific immunoadsorption therapy has the potential to ameliorate the course of Miller Fisher syndrome. This condition is typically a benign, self-limiting illness. Both plasmapheresis and intravenous immunoglobulin may be employed as treatment, especially in cases of Bickerstaff's brainstem encephalitis or those with overlapping Guillain-Barré syndrome. Anti-GQ1b antibody testing has allowed clinicians to develop a greater understanding of the spectrum of Miller Fisher syndromes and to refine clinical diagnoses in patients with unusual presentations. Experimental studies strongly suggest anti-GQ1b antibodies are pathogenic, which in principle should direct treatments towards antibody neutralization or elimination.Keywords
This publication has 40 references indexed in Scilit:
- Miller Fisher syndrome associated with Pasteurella multocida infectionJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathyBrain, 2004
- Acute ophthalmoparesis in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculiJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Síndrome de Miller-Fisher: hallazgos clínicos, infecciones asociadas y evolución en 8 pacientesMedicina Clinica, 2004
- Recurrent anti-GQ1b IgG antibody syndrome showing different phenotypes in different periodsJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive casesJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain–Barré and Fisher's syndromesJournal of Neuroimmunology, 1998
- Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter releaseThe Lancet, 1994
- Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.Journal of Neurology, Neurosurgery & Psychiatry, 1993